The DOI matches its Crossref record.
BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part II: analgesics and other drugs used in rheumatology practice: Table 1
Open accessAbstract
The prescribing of many drugs in pregnancy is complicated by a lack of knowledge regarding their compatibility, leading to patient misinformation and withdrawal/denial of disease-ameliorating therapies. This situation should be avoided because active rheumatic disease is associated with adverse pregnancy outcomes [ 1 ] and there is growing evidence of drug safety in pregnancy. To provide evidence-based recommendations, which do not imply a legal obligation, for clinicians to follow when prescribing drugs commonly used in the management of multisystem rheumatic conditions before/during pregnancy and breastfeeding, updating previous recommendations [ 2 , 3 ]. For recommendations on prescribing anti-rheumatic drugs in pregnancy and breastfeeding, see the BSR and BHPR guideline part I [ 4 ]. Health professionals directly involved in managing patients with rheumatic disease in the UK who are or are planning to become pregnant and/or breastfeeding, men planning to conceive and patients who have accidentally conceived while taking these medications. This guideline does not cover the management of infertility; acute pain relief during labour, hence morphine was excluded; or the indications for these drugs in specific rheumatic diseases in pregnancy. Specific questions were considered in relation to each drug. Should it be stopped pre-conception? Is it compatible with pregnancy? Is it compatible with breastfeeding? Where possible, recommendations are made regarding compatibility with paternal exposure. These findings are summarized in Table 1 . An accompanying description of evidence and full recommendations are given in the full guideline, available as supplementary data at Rheumatology Online. Summary of drug compatibility in pregnancy and breastfeeding For further information and caveats, see the relevant recommendations and main text in the executive summary and full guideline. a Intermittent use advised, see main text for details. b No studies identified, but unlikely to be harmful due to maternal compatibility. c Limited evidence, but unlikely to be harmful. d Insufficient evidence regarding use for treatment of chronic pain in pregnancy. e Possible association with miscarriage and malformation. f No studies identified, but unlikely to be harmful. ACEI: angiotensin-converting enzyme inhibitor; COX: cyclooxygenase; LMWH: low molecular weight heparin; MDT: multidisciplinary team. Paracetamol is compatible peri-conception and throughout pregnancy [level of evidence (LOE) 2+, grade of recommendation (GOR) C, strength of agreement (SOA) 100%]. Intermittent use is advised because of a small risk of wheeze and childhood asthma with prolonged paracetamol use in pregnancy (LOE 2+, GOR C, SOA 99.5%). Avoid regular use during weeks 8–14 of pregnancy due to a small reported risk of cryptorchidism (LOE 2+, GOR C, SOA 99.5%). LactMed describes paracetamol as a good choice for analgesia and fever reduction in breastfeeding mothers (LOE 4, GOR D, SOA 100%). There are no data on paternal exposure to paracetamol, but due to maternal compatibility, it is unlikely to be harmful (LOE 4, GOR D, SOA 99.5%). Codeine is compatible peri-conception and throughout pregnancy. There is no consistent evidence to recommend a dose reduction pre-delivery, but neonatologists should be aware of maternal use (LOE 2 ++, GOR C, SOA 100%). Caution is advised with the use of codeine in breastfeeding due to the risk of CNS depression resulting from unpredictable metabolism of codeine to morphine (LOE 2+, GOR D, SOA 98.4%). There are no data relating to paternal exposure to codeine, but due to maternal compatibility, it is unlikely to be harmful (LOE 4, GOR D, SOA 98.9%). Tramadol is compatible with pregnancy, although there have been no high-quality studies published investigating the safety of tramadol in pregnancy (LOE 2−, GOR D, SOA 98.4%). Based on limited data, tramadol may be compatible with short-term use in breastfeeding (LOE 2−, GOR D, SOA 97.9%). There are no data relating to paternal exposure to tramadol, but due to maternal compatibility, it is unlikely to be harmful (LOE 4, GOR D, SOA 98.9%). Amitriptyline is compatible with pregnancy (LOE 2+, GOR C, SOA 99.5%). Low-dose amitriptyline for chronic pain is unlikely to cause adverse effects in breastfed infants (LOE 4, GOR D, SOA 98.4%). There are no data relating to paternal exposure to amitriptyline, but due to maternal compatibility, it is unlikely to be harmful (LOE 4, GOR D, SOA 98.4%). There is insufficient evidence to recommend gabapentin for the treatment of chronic pain in pregnancy (LOE 2−, GOR D, SOA 99.5%). There is insufficient evidence to recommend gabapentin for the treatment of chronic pain in breastfeeding (LOE 4, GOR D, SOA 100%). There are no data to recommend pregabalin in pregnancy or when breastfeeding (LOE 4, GOR D, SOA 100%). There are no data on which to base a recommendation regarding paternal exposure to gabapentin or pregabalin (SOA 100%). Venlafaxine is compatibl
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Andreoli, L., Bertsias, G. K., Agmon-Levin, N., Brown, S., Cervera, R., Costedoat-Chalumeau, N., Doria, A., Fischer-Betz, R., Forger, F., Moraes-Fontes, M. F., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209770 · Cited by 945
Self-citationSammaritano, L. R., Bermas, B. L., Chakravarty, E. E., Chambers, C., Clowse, M. E. B., Lockshin, M. D., Marder, W., Guyatt, G., Branch, D. W., Buyon, J., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41191 · Cited by 790
Flint, J., Panchal, S., Hurrell, A., van de Venne, M., Gayed, M., Schreiber, K., Arthanari, S., Cunningham, J., Flanders, L., Moore, L., et al. (2016) · Rheumatology · doi:10.1093/rheumatology/kev404 · Cited by 451
Self-citationGordon, C., Amissah-Arthur, M.-B., Gayed, M., Brown, S., Bruce, I. N., D’Cruz, D., Empson, B., Griffiths, B., Jayne, D., Khamashta, M., et al. (2018) · Rheumatology · doi:10.1093/rheumatology/kex286 · Cited by 365
Self-citationSchreiber, K., Sciascia, S., de Groot, P. G., Devreese, K., Jacobsen, S., Ruiz-Irastorza, G., Salmon, J. E., Shoenfeld, Y., Shovman, O., & Hunt, B. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.103 · Cited by 359
Self-citation
Metadata
- Authors
- Flint, J., Panchal, S., Hurrell, A., van de Venne, M., Gayed, M., Schreiber, K., Arthanari, S., Cunningham, J., Flanders, L., Moore, L., Crossley, A., Purushotham, N., Desai, A., Piper, M., Nisar, M., Khamashta, M., Williams, D., Gordon, C., Giles, I., & on behalf of the BSR and BHPR Standards, G. A. A. W. G.
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-01-10
- Volume
- 55
- Issue
- 9
- Pages
- 1698-1702
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- OpenAlex
- W2233772593
- Cited by
- 161
- References
- 0
- FWCI
- 19.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part II: analgesics and other drugs used in rheumatology practice: Table 1. https://app.cochat.ai/papers/10.1093/rheumatology/kev405
- The paper
- Flint, J., Panchal, S., Hurrell, A., van de Venne, M., Gayed, M., Schreiber, K., Arthanari, S., Cunningham, J., Flanders, L., Moore, L., Crossley, A., Purushotham, N., Desai, A., Piper, M., Nisar, M., Khamashta, M., Williams, D., Gordon, C., Giles, I., & on behalf of the BSR and BHPR Standards, G. A. A. W. G. (2016). BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part II: analgesics and other drugs used in rheumatology practice: Table 1. Rheumatology. https://doi.org/10.1093/rheumatology/kev405
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.